Literature DB >> 29725413

Expression levels of the runt-related transcription factor 1 and 3 genes in the development of acute myeloid leukemia.

Adrian Krygier1, Dagmara Szmajda1, Marta Żebrowska1, Agnieszka Jeleń1, Ewa Balcerczak1.   

Abstract

The aim of the present study was to evaluate the mRNA expression level of the runt-related transcription factor 1 (RUNX1) and runt-related transcription factor 3 (RUNX3) genes in patients with acute myeloid leukemia (AML). The etiology of AML is not yet fully known, but certain genetic factors may contribute to its manifestation. The RUNX1 and RUNX3 genes have been demonstrated to serve a role in the transcription process. The group investigated in the present study included 43 patients diagnosed with AML, and the relative RUNX1 and RUNX3 expression levels were determined using reverse transcription-quantitative polymerase chain reaction. The results indicated that RUNX1 and RUNX3 expression was associated with clinicopathological features, including sex and mortality risk. Expression levels of the RUNX1 gene were higher and more variable among females (P=0.044), and mortality was more frequent among patients with a higher RUNX3 expression level (P=0.036). The data obtained from the present study suggested that RUNX3 expression may have potential value as a prognostic factor; furthermore, sex is potentially a factor that may affect the difference in RUNX1 gene expression level among females and males. Further analyses in this field will aid in the identification and elucidation of the molecular basis of leukemia.

Entities:  

Keywords:  acute myeloid leukemia; expression level; reverse transcription-quantitative polymerase chain reaction; runt-related transcription factor 1; runt-related transcription factor 3

Year:  2018        PMID: 29725413      PMCID: PMC5920506          DOI: 10.3892/ol.2018.8143

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development.

Authors:  Ichiro Taniuchi; Motomi Osato; Takeshi Egawa; Mary Jean Sunshine; Suk Chul Bae; Toshihisa Komori; Yoshiaki Ito; Dan R Littman
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

Review 3.  Acute Myeloid Leukemia.

Authors:  Hartmut Döhner; Daniel J Weisdorf; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 4.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 5.  Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.

Authors:  Michael Medinger; Claudia Lengerke; Jakob Passweg
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

6.  Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia.

Authors:  F Otto; M Stock; M Fliegauf; P Fenaux; C Preudhomme; M Lübbert
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

Review 7.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.

Authors:  Motomi Osato
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 8.  Tumor suppressor activity of RUNX3.

Authors:  Suk-Chul Bae; Joong-Kook Choi
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

Review 9.  RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.

Authors:  Kentson Lam; Dong-Er Zhang
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

10.  High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.

Authors:  Lin Fu; Huaping Fu; Lei Tian; Keman Xu; Kai Hu; Jing Wang; Jijun Wang; Hongmei Jing; Jinlong Shi; Xiaoyan Ke
Journal:  Oncotarget       Date:  2016-03-29
View more
  4 in total

1.  RUNX3/H3K27me3 Co-Expression Defines a Better Prognosis in Surgically Resected Stage I and Postoperative Chemotherapy-Naive Non-Small-Cell Lung Cancer.

Authors:  Xiaohui Chen; Yujie Deng; Chuanzhong Huang; Yi Shi; Jianping Lu; Guibin Weng; Weifeng Zhu; Kunshou Zhu; Junqiang Chen; Jiancheng Li
Journal:  J Oncol       Date:  2022-03-24       Impact factor: 4.375

2.  RUNX1 and RUNX3 Genes Expression Level in Adult Acute Lymphoblastic Leukemia-A Case Control Study.

Authors:  Dagmara Szmajda-Krygier; Adrian Krygier; Krzysztof Jamroziak; Anna Korycka-Wołowiec; Marta Żebrowska-Nawrocka; Ewa Balcerczak
Journal:  Curr Issues Mol Biol       Date:  2022-08-01       Impact factor: 2.976

Review 3.  RUNX family: Oncogenes or tumor suppressors (Review).

Authors:  Beatriz Andrea Otálora-Otálora; Berta Henríquez; Liliana López-Kleine; Adriana Rojas
Journal:  Oncol Rep       Date:  2019-05-06       Impact factor: 3.906

4.  Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development.

Authors:  Adrian Krygier; Dagmara Szmajda-Krygier; Aleksandra Sałagacka-Kubiak; Krzysztof Jamroziak; Marta Żebrowska-Nawrocka; Ewa Balcerczak
Journal:  Med Oncol       Date:  2020-11-10       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.